Commercialization of Stem Cells
02/06/08
5:30 pm-8:30 pm
UK Trade & Investment, One Memorial Drive, Cambridge
5:30 pm-8:30 pm
UK Trade & Investment, One Memorial Drive, Cambridge
At this year’s Bio Forum panel, put on by Mass High Tech, a group of industry, university, and investor experts will put the issue of commercialization of stem cells, skin cell therapies, and therapeutic proteins under the microscope, so to speak.
Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.
1/26/08 9:13 am
1. Autologous stem cells have been proven safe in anecdotal and clinical studies for years in many parts of the world…There needs to be a differentiation between chemically based and/or donor therapies from patient derived miminally manipulated cell therapies within the FDA. We need to lift the regulatory burdens that are unnecessary in autologous stem cell products.
2. All chemically based therapeutic compounds should first be tested on human cells preclinical, rather than immune suppressed animal testing, before use on live human patients.